- Home
- DFDV vs ALDX Comparison
DFDV vs ALDX Comparison
Compare DFDV & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFDV
- ALDX
- Stock Information
- Founded
- DFDV 2018
- ALDX 2004
- Country
- DFDV United States
- ALDX United States
- Employees
- DFDV N/A
- ALDX N/A
- Industry
- DFDV Finance: Consumer Services
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- DFDV Finance
- ALDX Health Care
- Exchange
- DFDV Nasdaq
- ALDX Nasdaq
- Market Cap
- DFDV 330.2M
- ALDX 313.4M
- IPO Year
- DFDV N/A
- ALDX 2014
- Fundamental
- Price
- DFDV $15.79
- ALDX $5.74
- Analyst Decision
- DFDV Buy
- ALDX Strong Buy
- Analyst Count
- DFDV 1
- ALDX 2
- Target Price
- DFDV $45.00
- ALDX $9.50
- AVG Volume (30 Days)
- DFDV 2.3M
- ALDX 752.1K
- Earning Date
- DFDV 11-05-2025
- ALDX 11-06-2025
- Dividend Yield
- DFDV N/A
- ALDX N/A
- EPS Growth
- DFDV N/A
- ALDX N/A
- EPS
- DFDV 1.17
- ALDX N/A
- Revenue
- DFDV $3,520,660.00
- ALDX N/A
- Revenue This Year
- DFDV $70.03
- ALDX N/A
- Revenue Next Year
- DFDV $142.86
- ALDX $36.23
- P/E Ratio
- DFDV $13.47
- ALDX N/A
- Revenue Growth
- DFDV 97.13
- ALDX N/A
- 52 Week Low
- DFDV $0.49
- ALDX $1.14
- 52 Week High
- DFDV $53.88
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- DFDV 47.47
- ALDX 65.02
- Support Level
- DFDV $14.93
- ALDX $5.13
- Resistance Level
- DFDV $16.35
- ALDX $5.43
- Average True Range (ATR)
- DFDV 1.05
- ALDX 0.23
- MACD
- DFDV 0.00
- ALDX 0.05
- Stochastic Oscillator
- DFDV 29.98
- ALDX 98.97
About DFDV DeFi Development Corp. Common Stock
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.